Table 4. The predicted mean percentages of the subjects with γ-GT elevation and the mean odds ratios (95% CIs) for γ-GT elevation during VPA therapy according to the SOD2 Val16Ala genotype and complication with intellectual disability when different daily doses of VPA were administered to patients without any co-treatment.

Dose (mg)	Intellectualdisability	SOD2 genotype	γ-GTelevation (%)	Odds ratio (95% CIs)
400	–	Val/Ala or Ala/Ala	5.8	1
	–	Val/Val	13.0	2.42 (1.75–3.34)
	+	Val/Ala or Ala/Ala	24.9	5.38 (3.98–7.27)
	+	Val/Val	42.4	11.91 (8.89–15.98)
500	–	Val/Ala or Ala/Ala	6.0	1
	–	Val/Val	14.1	2.56 (1.87–3.51)
	+	Val/Ala or Ala/Ala	25.5	5.32 (3.95–7.16)
	+	Val/Val	43.8	12.12 (9.08–16.17)
600	–	Val/Ala or Ala/Ala	5.2	1
	–	Val/Val	16.9	3.67 (2.66–5.07)
	+	Val/Ala or Ala/Ala	27.8	6.96 (5.10–9.49)
	+	Val/Val	44.8	14.68 (10.82–19.91)
700	–	Val/Ala or Ala/Ala	7.7	1
	–	Val/Val	17.2	2.50 (1.88–3.32)
	+	Val/Ala or Ala/Ala	30.6	5.30 (4.05–6.94)
	+	Val/Val	48.1	11.17 (8.58–14.54)
800	–	Val/Ala or Ala/Ala	9.4	1
	–	Val/Val	20.2	2.44 (1.88–3.17)
	+	Val/Ala or Ala/Ala	31.6	4.47 (3.48–5.74)
	+	Val/Val	52.6	10.74 (8.30–13.75)
900	–	Val/Ala or Ala/Ala	9.6	1
	–	Val/Val	21.1	2.52 (1.94–3.27)
	+	Val/Ala or Ala/Ala	34.9	5.04 (3.94–6.46)
	+	Val/Val	55.6	11.77 (9.22–15.03)
1000	–	Val/Ala or Ala/Ala	10.8	1
	–	Val/Val	24.2	2.65 (2.07–3.39)
	+	Val/Ala or Ala/Ala	35.6	4.57 (3.60–5.80)
	+	Val/Val	56.2	10.63 (8.40–13.46)
1100	–	Val/Ala or Ala/Ala	13.1	1
	–	Val/Val	27.8	2.55 (2.02–3.20)
	+	Val/Ala or Ala/Ala	42.6	4.90 (3.93–6.13)
	+	Val/Val	57.8	9.05 (7.24–11.30)
1200	–	Val/Ala or Ala/Ala	14.8	1
	–	Val/Val	28.1	2.25 (1.80–2.81)
	+	Val/Ala or Ala/Ala	46.6	5.01 (4.04–6.20)
	+	Val/Val	65.3	10.83 (8.71–13.46)

γ-GT: γ-glutamyltransferase; VPA = valproic acid; Dose = daily dose of VPA; SOD2 = superoxide dismutase 2; CIs = confidence intervals; − = absent; + = present.